Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin A - Ipsen Limited

Next Previous
Search
Drug Profile

Botulinum toxin A - Ipsen Limited

Alternative Names: Clostridium botulinum neurotoxin serotype A, recombinant - Ipsen Innovation; IPN 59011; Modified recombinant botulinum neurotoxin serotype A - Ipsen Innovation

Latest Information Update: 06 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ipsen Limited
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Facial wrinkles; Muscle spasticity

Most Recent Events

  • 23 Dec 2022 Ipsen terminates a phase-I/II trial in Facial wrinkles in Germany due to strategic considerations (NCT04736745)
  • 01 Apr 2021 Ipsen reinitiates a phase I/II trial in Facial wrinkles in Germany (IM) (NCT04736745) (EudraCT2019-003268-33)
  • 02 Mar 2021 Ipsen suspends a phase I/II trial in Facial Wrinkles due to internal investigation of an unexpected result in drug product stability study in Germany (IM) before March 2021 (NCT04736745)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top